John C. Thomas Jr.

Form D signer

John C. Thomas Jr.

Chief Financial Officer of the Issuer at CoRegen

Form D signer

Capital raised by CoRegen

$96.9M+$13.5M latest round

3 Form D filings · first filed Jan 2025 · Aspen, CO

CURRENT ROLE: Chief Financial Officer of the Issuer
SECTOR: Biotech
COMPANY FILINGS: 3
TEAM ON FILE: 4
FOUNDED: 2022
30D INTEREST: 2 ↗

Career

1 company on file · founded 2022

CoRegenBiotech · Aspen, COsince 2022

Chief Financial Officer of the Issuer

Signatory on CoRegen's Form D filings · $96.9M raised across 3

Company filings

via EDGAR · Form D for CoRegen3

DateCompanyFormAmountRole on filing

Oct 28, 2025CoRegenForm D+$13.5MChief Financial Officer of the Issuer

Form DOct 28, 2025 · CoRegen+$13.5Mas Chief Financial Officer of the Issuer

Apr 21, 2025CoRegenForm D+$62.6MChief Financial Officer of the Issuer

Form DApr 21, 2025 · CoRegen+$62.6Mas Chief Financial Officer of the Issuer

Jan 19, 2025CoRegenForm D+$20.8MChief Financial Officer of the Issuer

Form DJan 19, 2025 · CoRegen+$20.8Mas Chief Financial Officer of the Issuer

Overview

Last filing Oct 28, 2025

John C. Thomas Jr. is on file as Chief Financial Officer of the Issuer at CoRegen in Aspen, CO. CoRegen has 3 Form D filings on record, $96.9M raised in total. John C. Thomas Jr. appears as a signatory on the company's filings.

Teammates

CoRegen · 3

Jonathan SimonsDirector Peter GelinasExecutive Officer Sonja NelsonChief Financial OfficerSigner

Products

CoRegen · 1

Novel Cancer TherapyCancer Therapy

CoRegen's main product is a cutting-edge cancer therapy designed to modify regulatory T cells (Tregs) with the aim of eliminating tumors and preventing their recurrence. The therapy focuses on effectively enhancing the immune response against cancer cells.